Final analysis: TC (docetaxel/cyclophosphamide, 4 cycles) has a superior disease-free survival compared to standard AC (doxorubicin/cyclophosphamide) in 1016 women with early stage breast cancer

被引：0

作者：

Jones, SE ^{[1
]}

Savin, MA ^{[1
]}

Holmes, FA ^{[1
]}

O'Shaughnessy, JA ^{[1
]}

Blum, JL ^{[1
]}

Vukelja, SJ ^{[1
]}

George, TK ^{[1
]}

McIntyre, KJ ^{[1
]}

Pippen, JE ^{[1
]}

Sandbach, J ^{[1
]}

Kirby, RL ^{[1
]}

Bordelon, JH ^{[1
]}

Hyman, WJ ^{[1
]}

Negron, AG ^{[1
]}

Khandelwal, P ^{[1
]}

Richards, DA ^{[1
]}

Anthony, S ^{[1
]}

Nugent, JE ^{[1
]}

Mennel, RG ^{[1
]}

Banerji, M ^{[1
]}

Edelman, G ^{[1
]}

Ruxer, RL ^{[1
]}

Amare, M ^{[1
]}

Kampe, CE ^{[1
]}

Koutrelakos, N ^{[1
]}

Meyer, WG ^{[1
]}

Asmar, L ^{[1
]}

机构：

[1] US Oncol Res Inc, Houston, TX USA

来源：

BREAST CANCER RESEARCH AND TREATMENT | 2005年 / 94卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：S20 / S20

页数：1

共 49 条

[1] Four versus six cycles of docetaxel and cyclophosphamide (TC) in early stage hormone positive breast cancer
Basu, Aparna
Dabak, Vrushali S.
Loutfi, Randa
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
[2] Adjuvant docetaxel plus doxorubicin and cyclophosphamide increases survival compared with fluorouracil plus doxorubicin and cyclophosphamide in women with operable node-positive breast cancer
Roy, V
Perez, EA
[J]. CANCER TREATMENT REVIEWS, 2006, 32 (01) : 55 - 58
[3] Four vs six cycles of docetaxel and cyclophosphamide (TC) in early stage triple-negative breast cancer
Basu, Aparna
Mohammed, Hadi A.
Mahmood, Sharmeen
Dabak, Vrushali
Loutfi, Randa
[J]. CANCER RESEARCH, 2019, 79 (13)
[4] Comparison of overall and recurrence-free survival between four and six cycles of adjuvant docetaxel and cyclophosphamide in early stage breast cancer
Mehmi, I.
Wight, C. E.
Hill, J. L.
[J]. CANCER RESEARCH, 2019, 79 (04)
[5] Doxorubicin/cyclophosphamide with concurrent versus sequential docetaxel as neoadjuvant treatment in patients with breast cancer 5-year disease-free and overall survival data
Vriens, B.
Aarts, M.
Van Gastel, S.
Van den Berkmortel, F.
Smilde, T.
Van Warmerdam, L.
De Boer, M.
Van Spronsen, D. J.
Peer, P.
Tjan-Heijnen, V.
[J]. EUROPEAN JOURNAL OF CANCER, 2016, 57 : S100 - S100
[6] RATE OF FEBRILE NEUTROPENIA WITH DOCETAXEL/CYCLOPHOSPHAMIDE (TC) IN WOMEN WITH EARLY STAGE BREAST CANCER: AN AUSTRALIAN PUBLIC HOSPITAL EXPERIENCE
Pokharel, K.
Lovat, K.
Chern, B.
Bigby, K.
[J]. ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY, 2013, 9 : 42 - 42
[7] Docetaxel, carboplatin and trastuzumab (TCH) and doxorubicin/cyclophosphamide followed by docetaxel/trastuzumab (AC-TH) produce superior disease-free survival (DFS) compared to AC-T in patients (pts) with HER-2 positive early breast cancer (EBC), with increased cardiac toxicity confined to AC-TH: BCIRG 006 study
不详
[J]. EJC SUPPLEMENTS, 2006, 4 (02): : 108 - 109
[8] Analysis of Topoisomerase IIa and HER2 Status in 126 Patients from the US Oncology 9735 Trial of Adjuvant Chemotherapy with Docetaxel/Cyclophosphamide (TC) vs Doxorubicin/Cyclophosphamide (AC) in Early Breast Cancer
Aitelli, C. L.
Saad, R. D.
Mackey, D. W.
Asmar, L.
Jones, S.
Pippen, J.
[J]. CANCER RESEARCH, 2009, 69 (24) : 636S - 636S
[9] Sequential treatment of docetaxel plus doxorubicin/cyclophosphamide (AC) as first-line chemotherapy for metastatic breast cancer (MBC).: Final results and survival analysis of a phase II study
Antón, A
Colomer, R
Lluch, A
Massuti, B
Corral, M
[J]. EUROPEAN JOURNAL OF CANCER, 2002, 38 : S68 - S69
[10] Disease-free and overall survival at 3.5 years for neoadjuvant bevacizumab added to docetaxel followed by fluorouracil, epirubicin and cyclophosphamide, for women with HER2 negative early breast cancer: ARTemis Trial
Earl, H. M.
Hiller, L.
Dunn, J. A.
Blenkinsop, C.
Grybowicz, L.
Vallier, A. -L.
Gounaris, I.
Abraham, J. E.
Hughes-Davies, L.
McAdam, K.
Chan, S.
Ahmad, R.
Hickish, T.
Rea, D.
Caldas, C.
Bartlett, J. M. S.
Cameron, D. A.
Provenzano, E.
Thomas, J.
Hayward, R. L.
[J]. ANNALS OF ONCOLOGY, 2017, 28 (08) : 1817 - 1824

← 1 2 3 4 5 →